Elanco completed the acquisition of Prevtec Microbia for $60m.

Elanco Animal Health, which provides comprehensive products and knowledge services to improve animal health and food-animal production, completed the acquisition of Prevtec Microbia, a Canadian biotechnology company, for $60m. “Elanco’s partnership with Prevtec has been very successful and has resulted in delivery of an important non-antibiotic solution for swine producers. This acquisition is another example of our approach to partner with companies to introduce novel innovation and further demonstrates our commitment to introduce antibiotic alternatives through internal or external innovation pathways,” Ramiro Cabral, Elanco Executive Vice President.